Wedoany.com Report-Dec.18, INCOG BioPharma Services, a contract development and manufacturing organization, has revealed plans for a significant expansion of its injectable drug production facility in Fishers, Indiana, United States, involving an investment of approximately $200 million.

Digital rendering of INCOG's 21-acre campus.

The project will add around 300,000 square feet of dedicated space to the existing 21-acre campus, with construction beginning in early 2026. This enhancement is intended to position the site as a major global center for injectable biopharmaceutical manufacturing.

By 2030, the expanded operations are projected to support employment for nearly 1,000 individuals at the location.

State incentives from Indiana will contribute to developing advanced production infrastructure. The upgrades will strengthen capabilities in sterile fill/finish processes for injectable products, automated inspection, device assembly, labeling, serialization, and final packaging.

The facility is designed to achieve an annual output capacity of up to 480 million units.

INCOG BioPharma CEO Cory Lewis stated: "The continued demand from our global biopharma partners and our team's ability to deliver create the opportunity for this next level of investment and expansion. Committing another $200m and employing nearly 1,000 team members by 2030 underscores our dedication to continue providing world-class, flexible manufacturing capacity while creating generational opportunities for the talented workforce here in central Indiana."

INCOG BioPharma provides comprehensive services for sterile injectable drug products, covering both clinical and commercial stages for international biopharmaceutical clients.

The company focuses on filling complex, high-value molecules into vials, syringes, and cartridges. Additional offerings include device assembly—such as syringe accessorizing, needle safety devices, and autoinjectors—as well as complete packaging solutions and on-site analytical testing.

This expansion responds to growing requirements in the biopharmaceutical sector for reliable, scalable production of injectable therapies. By increasing capacity and incorporating modern technologies, the Fishers site will better serve diverse client needs across development and supply chains.

The investment reflects confidence in sustained demand for specialized manufacturing services, particularly in parenteral formulations that require stringent quality and precision.

Located in a region with established life sciences infrastructure, the campus benefits from access to skilled talent and supportive local initiatives. The phased growth approach allows for orderly integration of new areas while maintaining current operations.

Upon completion, the enhanced facility will contribute substantially to global availability of advanced injectable medicines, supporting innovation in treatments for various therapeutic areas.

INCOG BioPharma's end-to-end model enables seamless progression from formulation development through commercial distribution, offering flexibility for molecules at different lifecycle stages.

This strategic development reinforces the company's role in the contract manufacturing landscape, providing robust options for biopharmaceutical partners seeking efficient, high-quality production resources in North America.